Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06067698
NA

Alpha Lipoic Acid in Ulcerative Colitis

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.

Official title: Clinical Study Evaluating the Efficacy and Safety of Alpha-lipoic Acid in Patients With Ulcerative Colitis Treated With Mesalamine

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-10-01

Completion Date

2025-04-01

Last Updated

2025-02-06

Healthy Volunteers

No

Interventions

DRUG

"Mesalamine" and "alpha-lipoic acid"

Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months

DRUG

"Mesalamine" and "Placebo"

Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months

Locations (1)

Tanat university hospital

Tanta, Egypt